Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJames D’OlimpioAGAndrew Gillis-SmithSMShuo Ma

Discussion

Loading...

Member takes

Overview

Phase 1b study finds docirbrutinib improves anti-tumor responses in patients with B-cell lymphoma and CLL, suggesting efficacy against resistant mutations.

Key Points

  • To evaluate the safety and efficacy of docirbrutinib in patients with B-cell malignancies previously treated with BTK inhibitors.
  • Conducted a multicenter, open-label, Phase 1b study.
  • Included patients with chronic lymphocytic leukemia (CLL) or B-cell lymphoma who received ≥2 prior therapies.
  • Evaluated different dosing levels of docirbrutinib to determine the recommended Phase 2 dose.
  • Docirbrutinib demonstrated anti-tumor activities with durable responses in heavily treated CLL patients.
  • The median treatment duration was 6 months.
  • Responses included a 50% overall response rate in efficacy-evaluable CLL patients.

Cite This Study

D’Olimpio et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d860https://doi.org/10.1182/blood-2025-3892
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations2026
  2. 2Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients2025 · 5 citations
  3. 3Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study2025 · 7 citations
  4. 4Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study2026 · 2 citations
  5. 5Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor2025 · 2 citations